Raras
Buscar doenças, sintomas, genes...
Linfoma de Burkitt
ORPHA:543CID-10 · C91.8CID-11 · 2A85.6OMIM 113970DOENÇA RARA

Uma forma rara de linfoma não-Hodgkin maligno de células B maduras.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Uma forma rara de linfoma não-Hodgkin maligno de células B maduras.

Pesquisas ativas
7 ensaios
955 total registrados no ClinicalTrials.gov
Publicações científicas
4.618 artigos
Último publicado: 2026 Apr 16

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
12.5
Africa
Início
All ages
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: C91.8
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫃
Digestivo
6 sintomas
🩸
Sangue
3 sintomas
🦴
Ossos e articulações
1 sintomas
🛡️
Imunológico
1 sintomas

+ 7 sintomas em outras categorias

Características mais comuns

55%prev.
Morfologia anormal das células da medula óssea
Frequente (79-30%)
55%prev.
Neoplasia da cavidade oral
Frequente (79-30%)
55%prev.
Aumento da concentração circulante de lactato desidrogenase
Frequente (79-30%)
55%prev.
Hiperuricemia
Frequente (79-30%)
17%prev.
Náusea e vômito
Ocasional (29-5%)
17%prev.
Morfologia anormal do ovário
Ocasional (29-5%)
18sintomas
Frequente (4)
Ocasional (10)
Sem dados (4)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 18 características clínicas mais associadas, ordenadas por frequência.

Morfologia anormal das células da medula ósseaAbnormality of bone marrow cell morphology
Frequente (79-30%)55%
Neoplasia da cavidade oralNeoplasm of the oral cavity
Frequente (79-30%)55%
Aumento da concentração circulante de lactato desidrogenaseIncreased circulating lactate dehydrogenase concentration
Frequente (79-30%)55%
HiperuricemiaHyperuricemia
Frequente (79-30%)55%
Náusea e vômitoNausea and vomiting
Ocasional (29-5%)17%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico4.618PubMed
Últimos 10 anos200publicações
Pico2025145 papers
Linha do tempo
2026Hoje · 2026🧪 1988Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Not applicable.

MYCMyc proto-oncogene proteinPart of a fusion gene inAltamente restrito
FUNÇÃO

Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3' (PubMed:24940000, PubMed:25956029). Activates the transcription of growth-related genes (PubMed:24940000, PubMed:25956029). Binds to the VEGFA promoter, promoting VEGFA production and subsequent sprouting angiogenesis (PubMed:24940000, PubMed:25956029). Regulator of somatic reprogramming, controls self-renewal of embryonic stem cells (By similarity). Functions with TAF

LOCALIZAÇÃO

Nucleus, nucleoplasmNucleus, nucleolusNucleusCytoplasmChromosome

VIAS BIOLÓGICAS (10)
Cyclin A:Cdk2-associated events at S phase entryTranscription of E2F targets under negative control by DREAM complexCyclin E associated events during G1/S transition SMAD2/SMAD3:SMAD4 heterotrimer regulates transcriptionNOTCH1 Intracellular Domain Regulates Transcription
EXPRESSÃO TECIDUAL(Ubíquo)
Skin Not Sun Exposed Suprapubic
298.8 TPM
Fallopian Tube
238.6 TPM
Adipose Visceral Omentum
208.5 TPM
Linfócitos
195.3 TPM
Fibroblastos
193.2 TPM
OUTRAS DOENÇAS (3)
Burkitt lymphomaprecursor T-cell acute lymphoblastic leukemiahigh grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement
HGNC:7553UniProt:P01106

Medicamentos aprovados (FDA)

1 medicamento encontrado nos registros da FDA americana.

💊 Rituxan (RITUXIMAB)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

62 variantes patogênicas registradas no ClinVar.

🧬 MYC: GRCh37/hg19 8q24.13-24.3(chr8:126446968-146295771)x3 ()
🧬 MYC: NM_002467.6(MYC):c.31-11C>A ()
🧬 MYC: NM_002467.6(MYC):c.14G>A (p.Arg5Gln) ()
🧬 MYC: GRCh37/hg19 8q23.2-24.3(chr8:111432348-146295771)x3 ()
🧬 MYC: GRCh37/hg19 8q24.11-24.22(chr8:118071721-132774256)x1 ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 5 variantes classificadas pelo ClinVar.

5
Patogênica (100.0%)
VARIANTES MAIS SIGNIFICATIVAS
BRCA1: NM_007294.4(BRCA1):c.2885A>G (p.Glu962Gly) [Conflicting classifications of pathogenicity]
PMS2: NM_000535.7(PMS2):c.736_741delinsTGTGTGTGAAG (p.Pro246_Pro247delinsCysValTer) [Pathogenic]
MYC: NM_002467.6(MYC):c.162G>C (p.Glu54Asp) [Pathogenic]
MYC: NM_002467.6(MYC):c.302A>C (p.Asn101Thr) [Pathogenic]
MYC: NM_002467.6(MYC):c.214C>T (p.Pro72Ser) [Pathogenic]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
2Fase 28
1Fase 11
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 10 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Linfoma de Burkitt

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

6 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

955 ensaios clínicos encontrados, 7 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
2.021 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 2.021

#1

Single-cell profiling of HDAC inhibitor-induced EBV lytic heterogeneity defines abortive and refractory states in B lymphoblasts.

PLoS pathogens2026 Mar 23

Epstein-Barr virus (EBV) is associated with multiple malignancies including Burkitt lymphoma (BL), Hodgkin's lymphomas, nasopharyngeal carcinomas (NPC), and gastric cancers. Canonically, EBV positive tumors display latent gene expression programs that are difficult to target pharmacologically. To overcome this hurdle, lytic reactivation therapies have been developed based on HDAC inhibition with limited mechanistic studies. We therefore characterized the impact of pan-HDAC inhibitor, panobinostat, and class I HDAC inhibitor, nanatinostat, on the growth, survival, and lytic reactivation of four EBV-positive cell lines: P3HR1-ZHT BL, Jijoye BL, IBL-1 immunoblastic lymphoma, and de novo infection derived lymphoblastoid cell lines (LCL). All lines were sensitive, enabling us to define ranges of sensitivity within which to use single cell approaches to assess early EBV lytic gene expression, cell cycle state, and apoptosis. We observed that each EBV-positive model of malignancy responded uniquely to the same HDAC inhibitors and that lytic reactivation was successful in only a small percentage of the cell population. To elucidate the potential role of host factors in preventing successful lytic reactivation, we performed single-cell RNA sequencing on the P3HR1-ZHT BL line treated with the HDAC inhibitor panobinostat. We observed that abortive lytic cells, or cells that do not successfully progress through the lytic cycle, upregulated genes downstream of NF-κB activity. Additionally, genes involved in immune signaling including the CD137/CD137L signaling axis, were upregulated in abortive lytic cells. Functional validation through a Cas9-RNP approach revealed that the CD137 receptor is indeed involved in preventing successful lytic reactivation. These data have important implications for how we approach oncolytic therapies for EBV-associated malignancies.

#2

Association of MMP-2 and MMP-9 Polymorphisms and the Pathogenesis of Childhood Burkitt's Lymphoma.

Pediatric blood &amp; cancer2026 Mar 15

Burkitt lymphoma (BL) is a highly aggressive and invasive non-Hodgkin lymphoma derived from germinal center B cells and represents one of the most common childhood malignancies. Matrix metalloproteinases (MMPs) play a critical role in cancer progression by remodeling the extracellular matrix and modulating the tumor microenvironment. In advanced stages, MMPs facilitate tumor invasion and metastasis through the degradation of extracellular matrix components. This study aimed to investigate the association between MMP-2 and MMP-9 gene polymorphisms and the pathogenesis of childhood BL. This study was conducted at the Pediatric Oncohematology Center of the University of Pernambuco between 2021 and 2023 and included patients of both sexes aged 1 to 18 years diagnosed with BL between 1993 and 2023. Genomic DNA was extracted from peripheral blood samples using the salting-out method. Polymorphisms were identified by real-time polymerase chain reaction (PCR) using the TaqMan system. A total of 56 patients diagnosed with BL were analyzed; most were male, with a mean age of 7.1 years. The overall survival rate was 92.6%. A protective effect of the mutant TT genotype was observed compared to the wild-type CC genotype (OR = 0.0562; 95% CI: 0.0068-0.4644; p = 0.0016) for the MMP-2 polymorphism. Furthermore, individuals carrying the mutant G allele showed a positive association with BL compared to the wild-type A allele (G vs. A: OR = 1.9920; 95% CI: 1.1812-3.3594; p = 0.0130). These findings contribute to a better understanding of the genetic factors influencing BL susceptibility and support the need for further functional and large-scale studies to elucidate the mechanistic role of MMP-2 and MMP-9 polymorphisms in BL pathogenesis.

#3

Epstein-Barr virus-associated lymphoma: current understanding and treatment strategies.

Blood research2026 Mar 07

Epstein-Barr virus (EBV) infection is well-known for its high prevalence rate, association with several diseases including cancer and autoimmune conditions, and a wide variety of symptoms and prognosis. When acquired at a young age, primary infections are often asymptomatic; however, in adolescence and young adulthood, symptomatic infections develop, such as in infectious mononucleosis. A special feature of EBV infection is its ability to establish a latent infection in B cells which can lead to long-term infection. Subsequent cellular transformation and viral protein expression can result to EBV-mediated carcinogenesis. Latent proteins expressed by EBV play a role in the pathogenesis of EBV infection and carcinogenesis. These proteins are responsible for a diverse range of functions including cell transformation, cell reprogramming, immune evasion, immune suppression, angiogenesis, cell cycle regulation, and B-cell receptor mimicry.EBV infection is associated with diffuse large B-cell lymphoma, Hodgkin lymphoma, NK/T cell lymphoma, Burkitt lymphoma, post-transplant lymphoproliferative disorders, and primary CNS lymphoma. The clinical presentation varies depending on the specific disease and EBV status, with EBV-positive lymphomas generally associated with poorer prognosis than EBV-negative cases.This review aimed to examine the current understanding of the pathogenesis of EBV-associated lymphoma and to evaluate emerging and accepted therapeutic strategies.

#4

Global Patterns, Temporal Trends, and Potential Non-Infectious Risk Factors for Burkitt Lymphoma from 1990 to 2021.

Blood and lymphatic cancer : targets and therapy2026

The heterogeneity in the health burden and non-infectious risk factors of Burkitt lymphoma (BL) across sex, age, and geographic distribution remain inadequately understood. Based on Global Burden of Disease study 2021, we estimate the health burden of BL from four metrics: incidence, mortality, prevalence, and disability-adjusted life years. Subgroups were stratified by age, sex, region, and socio-demographic index (SDI). Joinpoint regression was used to evaluate the average annual percentage change (AAPC) to quantify trends in the health burden. Predictions were performed using the Bayesian age-period-cohort model. Non-infectious risk factors were identified and analyzed utilizing summary exposure values (SEVs) to assess their impact on BL incidence and mortality. The estimated global incident number of BL was 19,073 (95% CI: 9651 to 32,509) in 2021, nearly threefold that of 1990. The health burden of BL was markedly higher in males than females, especially among individuals aged under 20 years. From 1990 to 2021, the most significant increasing trend in BL health burden was observed in Cabo Verde, while Georgia exhibited the most notable decline. From 2021 to 2040, the global age-standardized incidence and mortality rates were projected to decline by 14.7% and 24.7%, respectively. Conversely, the health burden on individuals aged 20 to 54 years was anticipated to rise through 2040. In our study, low bone mineral density was found to be linked with elevated risk for males aged over 54 years, while childhood sexual abuse exhibited a paramount positive association with BL risk for females, regardless of age. Notably, tobacco use, particularly secondhand smoking, were inversely associated with BL risk across all age groups and sexes. Burkitt lymphoma demonstrated unique distribution patterns in terms of age, sex, and region. Further investigations into the heterogeneity of the risk factors for BL are essential for the development of more effective health policies and clinical practices.

#5

Implementation Science Methodology for the Successful Introduction of High-Dose Methotrexate for the Treatment of Pediatric Mature B-Cell Non-Hodgkin Lymphoma in a Resource-Limited Setting.

Pediatric blood &amp; cancer2026 Mar

Despite the excellent outcomes achieved for pediatric mature B-cell non-Hodgkin lymphoma (MB-NHL) in high-income countries, outcomes remain very poor in low- and middle-income countries. High-dose methotrexate (HD-MTX), which is highly efficacious for the disease, is still not commonly used in low-resource settings due to the potential for treatment-associated toxicity. Though there have been more recent reports of successful use of HD-MTX in resource-limited settings, there are no reports to date regarding the methodology used to safely introduce HD-MTX in these environments. Subsequently, at our treatment center in northern Tanzania, we endeavored to utilize implementation science methodology to elucidate generalizable methods to allow for a safe introduction of HD-MTX in a resource-limited setting. The Active Implementation Frameworks were utilized as a starting point to generate an initial implementation plan. Intervention fit was assessed, and resource mapping and cost analysis were completed. Key stakeholders were identified and engaged. Novel educational strategies, decision support tools, and protocol fidelity monitoring systems were developed. Following completion of all planning and education activities, use of a new HD-MTX containing MB-NHL protocol began in October of 2024. As of June 2025, 27 cycles of HD-MTX have been given to a cumulative total of 10 patients. Few protocol deviations have occurred, and only one Grade III non-hematologic adverse event has been reported. The use of implementation science methodology allowed a careful introduction of the use of HD-MTX for the treatment of pediatric MB-NHL in a resource-limited setting.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC2.017 artigos no totalmostrando 195

2026

Single-cell profiling of HDAC inhibitor-induced EBV lytic heterogeneity defines abortive and refractory states in B lymphoblasts.

PLoS pathogens
2026

[High-grade B-cell lymphoma with 11q aberration: A case report].

Annales de pathologie
2026

Trends and projections of Burkitt Lymphoma burden (1990-2036): an analysis based on the global burden of disease study 2021.

Hematology (Amsterdam, Netherlands)
2026

Treatment of Burkitt lymphoma in real-world setting: findings on 104 consecutive cases diagnosed and treated in Kazakhstan over the last decade.

Annals of hematology
2026

[EBNA1 Knockdown Modulates Proliferation, Apoptosis, and Metabolism in Burkitt's Lymphoma Cells by Downregulating miR-127-5p].

Zhongguo shi yan xue ye xue za zhi
2026

Locus-specific proteomics identifies novel regulators of Epstein-Barr virus lytic reactivation.

Journal of virology
2026

Pediatric Ileocecal Burkitt Lymphoma Presenting as a Diagnostic Challenge After a Nondiagnostic Surgical Biopsy: A Case Report.

Cureus
2026

Association of MMP-2 and MMP-9 Polymorphisms and the Pathogenesis of Childhood Burkitt's Lymphoma.

Pediatric blood &amp; cancer
2026

Epstein-Barr virus-associated lymphoma: current understanding and treatment strategies.

Blood research
2026

Refractory Burkitt Lymphoma Responding to an Accelerated Ramp-up of Glofitamab With Polatuzumab.

Clinical lymphoma, myeloma &amp; leukemia
2026

HIV-associated lymphoproliferative disorders: Single-center experience.

Medicine
2026

Case Report: Glofitamab in the treatment of a patient with central nervous system-involved Burkitt lymphoma.

Frontiers in oncology
2026

CD19 chimeric antigen receptor T-cell therapy for the treatment of a patient with refractory Burkitt lymphoma after kidney transplant.

Cytotherapy
2026

Massive Upper Gastrointestinal Bleeding With Splenomegaly due to Primary Gastric Burkitt Lymphoma in a Child.

Journal of paediatrics and child health
2026

Burkitt Lymphoma-A Guide to Biological Features, Diagnosis and Differential Diagnosis.

Cancers
2026

Minimal Disease Detection by Immunoglobulin High-Throughput Sequencing in Pediatric Burkitt Lymphoma.

Blood advances
2026

A Deep Dive Into Oncogenic Viruses Understanding Their Role in Cancer and Approaches for Prevention.

Reviews in medical virology
2026

Unusual case of follicular lymphoma of vocal cord.

Virchows Archiv : an international journal of pathology
2026

EBV Type 1 versus Type 2: A determinant of NK cell anti-tumor activity in Burkitt lymphoma.

bioRxiv : the preprint server for biology
2026

Is liquid biopsy a cost-effective method to diagnose Burkitt Lymphoma in children and young adults? A health economic evaluation in Tanzania.

BMC medicine
2026

Descriptive Case Series of Childhood Lymphomas Treated at the Children's Hospital of Mexico.

Pediatric reports
2026

The predictive value of immunohistochemistry for MYC, BCL2, and BCL6 in fluorescence in situ hybridization in aggressive mature B-cell lymphomas and re-evaluation according to the 5th edition of the World Health Organization classification: A single-center 9-year experience.

Indian journal of pathology &amp; microbiology
2026

Atypical Multisystemic Manifestations of Ascaris Infection in a Patient With Burkitt Lymphoma: A Fatal Diagnostic Challenge.

Cureus
2025

Challenges in delineating B-cell lymphoma: A case of plasmablastic lymphoma mimicking Burkitt lymphoma.

Journal of oral and maxillofacial pathology : JOMFP
2026

Durable Response to Glofitamab in HIV-Positive Refractory Burkitt Lymphoma: Case Report and Discussion.

EJHaem
2026

Routine Histopreparations After Tonsillectomy, Tonsillotomy, Adenotomy or Conchotomy: A Necessary Diagnosis in Times of Dwindling Resources?

Journal of clinical medicine
2026

Prospective Cohort Study Testing Interventions to Reduce Diagnosis Delay and Treatment Abandonment of Children With Burkitt Lymphoma in Kenya.

JCO global oncology
2026

miRNA profiling in pediatric and young adult Burkitt leukemia and lymphoma.

Virchows Archiv : an international journal of pathology
2026

The ancestral haplotype of P2RX5 yields a B-cell surface marker and a multi-lineage immunotherapy target.

bioRxiv : the preprint server for biology
2026

Glofitamab as a salvage therapy postallogenic hematopoietic stem cell transplant in relapsed-refractory Burkitt lymphoma.

Leukemia &amp; lymphoma
2026

Case Report: CD19 CAR-T therapy induces durable remission in a pediatric patient with TP53-mutated, refractory Burkitt lymphoma: a 30-month follow-up.

Frontiers in oncology
2026

Targeted panel sequencing for refining B-cell lymphoma diagnosis: a real-life, reference center experience.

Virchows Archiv : an international journal of pathology
2026

Molecular mechanisms of Epstein-Barr Virus in the pathogenesis of lymphomas and new opportunities for precision medicine.

Discover oncology
2026

[Diagnostic challenges in pediatric lymphomas].

Pathologie (Heidelberg, Germany)
2026

[An improved algorithm for genetic diagnostics of aggressive B-cell lymphomas in pediatric oncohematology: the experience of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology].

Arkhiv patologii
2026

Epigenetic dysregulation of B‑cells in autoimmune diseases and lymphomas (Review).

International journal of molecular medicine
2025

Case Report: A case of cervical burkitt lymphoma and literature review.

Frontiers in oncology
2025

Global initiative for childhood six-indexed cancers: how are we faring in Nigeria?

Ecancermedicalscience
2026

Diagnostic challenges in Burkitt's lymphoma with skull base and paravertebral involvement, and hearing loss: a case report.

Journal of medical case reports
2026

Germline Homozygous RAG1 Missense Variant Associated With Epstein-Barr Virus Negative Childhood Burkitt Lymphoma: A Case Report.

Journal of pediatric hematology/oncology
2026

A rare type of gastric malignancy: primary gastric Burkitt lymphoma.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
2026

Global Patterns, Temporal Trends, and Potential Non-Infectious Risk Factors for Burkitt Lymphoma from 1990 to 2021.

Blood and lymphatic cancer : targets and therapy
2026

Global, regional, and national burden of lymphoma from 1990 to 2021: a comprehensive analysis based on the global burden of disease study 1990-2021.

European journal of medical research
2025

Burkitt Lymphoma Presenting as Acute Abdomen: Beyond Infection and Diverticulitis.

Cureus
2026

Implementation Science Methodology for the Successful Introduction of High-Dose Methotrexate for the Treatment of Pediatric Mature B-Cell Non-Hodgkin Lymphoma in a Resource-Limited Setting.

Pediatric blood &amp; cancer
2026

CD47 blockade-driven necroptosis complements BCL-2 inhibition-driven apoptosis in lymphoid malignancies.

Journal of hematology &amp; oncology
2026

Cardiac mass in a patient with HIV infection: A case report and literature review.

Experimental and therapeutic medicine
2025

Mitochondrial calcium shapes B cell signaling and mitochondrial function.

Frontiers in immunology
2026

[Pediatric burkitt lymphoma primarily involving the adenoids: a case report and literature review].

Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery
2025

Higher chemical complementarity of EBV epitopes and IGH CDR3s correlates with better outcomes for lymphoma and ovarian cancer.

Cancer causes &amp; control : CCC
2025

Dissecting Epstein-Barr Virus Dependence Across Diverse Infected Cell Models.

bioRxiv : the preprint server for biology
2025

Malignancy Ratio in Pediatric Patients with Hereditary Multiple Exostoses: True Association or Reporting Bias?

Pediatric reports
2025

The Use of Single Dose of Rasburicase for the Prophylaxis and Treatment of Tumor Lysis Syndrome in Pediatric Patients: A Narrative Review.

Hematology reports
2025

Epstein-Barr virus infection shapes the genetic, transcriptomic, and immune microenvironment landscape of Burkitt lymphoma.

Infectious agents and cancer
2025

Childhood cancer survival in low- and middle-income countries and the Global South: emerging evidence and critical gaps from a scoping review of observational studies.

EJC paediatric oncology
2025

Epstein-Barr virus-associated lymphomas: biology, molecular genomics and precision oncology.

Frontiers in oncology
2025

Simultaneous auto-transplant and CD19 CAR T-cell 2nd line therapy followed by CD20 × CD3 bispecific antibody for refractory Burkitt lymphoma, a case report.

Leukemia &amp; lymphoma
2025

Impact of infection and microbial exposures on pediatric cancer.

Current problems in pediatric and adolescent health care
2025

Terminal ileum Burkitt's lymphoma related ileocolic intussusception in a five-year-old child: a case report and review of literature.

International journal of surgery case reports
2025

Bilateral jaw involvement of Burkitt's lymphoma in a 5-year-old: Rare pediatric case with review of the literature.

International journal of surgery case reports
2025

A rare case of large B-cell lymphoma with IRF4 rearrangement and concomitant 11q aberrations: a diagnostic pitfall in the molecular era.

Virchows Archiv : an international journal of pathology
2025

A Phase 1 Trial of Fimepinostat in Children and Adolescents With Relapsed and Refractory Solid and CNS Tumors.

Cancer medicine
2026

Clinical and molecular variations in Burkitt lymphoma.

Translational oncology
2025

Polatuzumab vedotin plus rituximab with chemotherapy in newly diagnosed pediatric stage IV Burkitt lymphoma: case report highlighting early complete remission.

Frontiers in immunology
2025

Primary Burkitt Lymphoma of the Thyroid Gland With Underlying Hashimoto's Thyroiditis: A Case Report.

Cureus
2025

CD4 and CD8 T-cell response is dominated by IL-10-secreting cells in children with uncomplicated Plasmodium falciparum malaria.

ImmunoHorizons
2025

Precision targeting of autoreactive B cells in systemic lupus erythematosus using anti-9G4 idiotope synthetic immune receptor T cells.

bioRxiv : the preprint server for biology
2025

The Impact of Malaria-Induced Neutrophil Subset Shift and a Link to Burkitt Lymphoma.

bioRxiv : the preprint server for biology
2025

Arginine Metabolism Supports De Novo Pyrimidine Biosynthesis to Block DNA Damage and Maintain Epstein-Barr Virus Latency.

bioRxiv : the preprint server for biology
2025

Diagnostic challenge in Burkitt lymphoma of the mandible initially misdiagnosed as osteomyelitis: a case report.

Journal of pathology and translational medicine
2025

Proteomic analysis of Burkitt lymphoma tissues: insights into the impact of age and EBV infection on protein expression and molecular characteristics.

Discover oncology
2025

Nanomedicines for Delivery of Cytarabine: Effect of Carrier Structure and Spacer on the Anti-Lymphoma Efficacy.

Polymers
2026

SOHO State of the Art Updates and Next Questions | Diagnosis and Management of High-Grade B-Cell Lymphomas.

Clinical lymphoma, myeloma &amp; leukemia
2025

Germline Predisposition to Pediatric Lymphoid Malignancies: Genetic Tumor Syndromes Identified in a Single-Center Study.

Clinical laboratory
2025

Epstein-Barr virus-transformed B-cells from a hypoxia model of the germinal center requires external unsaturated fatty acids.

PLoS pathogens
2025

Survival Prediction in Middle-Aged and Elderly Patients With Burkitt Lymphoma: A Comprehensive Nomogram Approach Based on SEER Data.

Cancer medicine
2025

Burkitt Lymphoma Presentation with Oropharyngeal Mass of Tonsillar Fossa: A Case Report.

Clinical practice and cases in emergency medicine
2025

Analysis of the clinical characteristics and prognostic factors of multicenter childhood Burkitt leukemia.

Annals of hematology
2025

A narrative review on the lactic acidosis and hypoglycemia in burkitt lymphoma: navigating metabolic changes.

Annals of medicine and surgery (2012)
2025

Lysine-specific histone demethylase complex restricts Epstein-Barr virus lytic reactivation.

Nature microbiology
2025

TIMAP downregulation in Burkitt's lymphoma reveals key molecules and signaling pathways in B-cell lymphomagenesis.

Experimental biology and medicine (Maywood, N.J.)
2025

Subtype-specific progression of post-transplant lymphoproliferative disease (PTLD) in children: Implications for age-based surveillance and early intervention strategies.

Transplant immunology
2025

Novel Molecular Insights and Evolution of Less Toxic Therapeutic Strategies in Burkitt Lymphoma.

Cancers
2025

Global incidence of childhood cancer by subtype in 2022: a population-based registry study.

EClinicalMedicine
2025

Sporadic Orbital Burkitt Lymphoma in Pediatric Population: A Case Series and Review of the Literature.

Ophthalmic plastic and reconstructive surgery
2026

Secondary bilateral adrenal Burkitt lymphoma with hepatic and renal involvement in a 17-year-old patient: A rare case report and literature review.

Radiology case reports
2025

Burkitt Lymphoma Presenting With Acute Kidney Injury and Facial Nerve Palsy: A Case Report With Literature Review.

Clinical case reports
2025

EBV-miR-BART5-3p promotes the proliferation of Burkitt lymphoma cells via glycolytic pathway.

Annals of hematology
2025

Myeloid/lymphoid neoplasm with PCM1::JAK2 rearrangement presenting as secondary Burkitt lymphoma.

Annales de biologie clinique
2026

Withaferin A inhibits EBV-driven lymphomagenesis through multiple mechanisms, including EBNA1 degradation.

Blood
2025

Investigation of PD-L1 Expression in Various Non-Hodgkin's B-cell Lymphomas.

Iranian journal of pathology
2025

Primary Aggressive Oral Lymphomas (PAOL): A Narrative Review of Diagnosis, Molecular Features, Therapeutic Approaches, and the Integrated Role of Dentists and Hematologists.

Cancers
2025

Aging alters genomic instability at endogenous mutation hotspots in mice.

Scientific reports
2025

Vertebral Involvement in Pediatric Burkitt Lymphoma: A Case Report.

Cureus
2025

Global burden of childhood Burkitt lymphoma (1990-2021): epidemiological trends, regional disparities, and projections for 2035 from the Global Burden of Disease Study.

Frontiers in medicine
2025

Burkitt in disguise: clonal transformation of incidentally detected gallbladder diffuse large B-cell lymphoma in a liver transplant recipient.

International journal of hematology
2025

Targeting RAB7 in human B lymphoma by a small molecule inhibitor arrests tumor cell growth.

Frontiers in oncology
2025

Effect of blueberry extract on enhancement of radiosensitivity in non-Hodgkin lymphoma by modulating proliferation and apoptosis.

Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
2025

Early treatment-related morbidity and mortality of children with non-Hodgkin's lymphoma treated at Tikur Anbesa Specialized Hospital with modified ALCL protocol: prospective cohort study.

BMC cancer
2025

Primary Non-Hodgkin Lymphoma of the Urinary Bladder in the Paediatric Age Group: A Report of a Rare Case.

Cureus
2025

Grade 4 Mucositis Secondary to Methotrexate Use in a Pediatric Patient With Stage IV Burkitt Lymphoma: A Case Report.

Cureus
2025

Aflatoxin B1 induces subtle but coordinated histone modifications in Epstein-Barr virus infected and non-infected Burkitt lymphoma cells.

Environment international
2025

Of Tingible Bodies and Starry Skies: Control of Normal and Malignant Tissues Through Apoptotic Cell-Dependent Communication (ACDC).

Advances in experimental medicine and biology
2026

Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study.

Haematologica
2025

Clinical and molecular features of primary spinal epidural lymphomas.

Annals of hematology
2025

Efficacy of Pola-R-CHP and Autologous Stem Cell Transplantation in Untreated Burkitt Lymphoma: A Case Report.

The American journal of case reports
2025

Cerebral Venous Thrombosis in Pediatric Oncology: A Case of Burkitt Lymphoma.

Cureus
2025

EBV-positive Burkitt lymphoma arising in a patient with chronic lymphocytic leukaemia/small lymphocytic lymphoma: a case report.

Journal of clinical pathology
2025

[Therapeutic adaptations: Rationale, achievements and limits. Experience of GFAOP].

Bulletin du cancer
2025

Simultaneous Maxillofacial, Abdominal, and Bone Marrow Involvement in a Pediatric Patient With Epstein-Barr Virus-Associated Burkitt Lymphoma: A Case From India.

Cureus
2025

Burkitt Lymphoma: An Atypical Presentation and Dismal Outcome.

Cureus
2025

Intensive Treatment in Adult Burkitt Lymphoma with Lymphome Malin B (LMB) Regimen: Excellent Outcomes Despite Substantial Toxicity and Supportive Care Demands.

Cancers
2025

Isolated Intracranial Recurrence of Burkitt Lymphoma Complicated by Dural Thickening: A Case Report.

Cureus
2025

HIV-Associated Lymphomas: Updates from Pathogenesis to Treatment Strategies.

Current HIV research
2025

Significant Impact of Treatment Abandonment on Survival of Children With "Common and Curable" GICC Index Cancers in Sub-Saharan Africa-A Multicenter Prospective CANCaRe Africa Study.

Pediatric blood &amp; cancer
2025

Navigating Rare Presentations: Recurrent Burkitt Lymphoma Presenting as a Jejunal Mass.

Clinical case reports
2026

Imidazopyridine DSH65 induces intrinsic apoptosis and cell cycle arrest in burkitt lymphoma cells.

Naunyn-Schmiedeberg's archives of pharmacology
2025

Novel Role of the Epstein-Barr Virus Encoded Deubiquitinating Enzyme (BPLF1) in mTOR-Mediated Cell Growth and Proliferation Pathways.

Viruses
2025

Phosphorylation of c-Myc at Ser62 via the protein kinase activity of acetaldehyde dehydrogenase 18A1 promotes tumor growth.

Molecular therapy : the journal of the American Society of Gene Therapy
2025

Programmatically Efficient Separation of Immune Infiltrate and Tumor Gene Expression Overlap Potentials in a Big Data Setting: FASLG Gene Expression-related Survival Distinctions.

Cancer genomics &amp; proteomics
2025

[44Sc]Sc-CHX-A″-DTPA-RCCB6: A PET Tracer for Imaging CD70 Expression Across Latency Types of Burkitt Lymphoma.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
2025

Risk of lymphoma among people with HIV in the United States, 2001-2019.

Journal of the National Cancer Institute
2025

Clinical and functional characterization of a novel TNFRSF9 variant causing immune dysregulation with predisposition to EBV-driven lymphomagenesis.

Frontiers in immunology
2025

An Atypical Case of Burkitt Lymphoma With MYC Gain and Cryptic IGH::MYC Rearrangement Detected by Rapid Nanopore Sequencing.

International journal of laboratory hematology
2025

Primary Burkitt Lymphoma of the Thyroid Associated With Hashimoto Thyroiditis Masquerading as Post-COVID Thyroiditis.

JCEM case reports
2026

Two decades of single-institution data reveal rare longterm survivors of relapsed/refractory Burkitt lymphoma.

Haematologica
2025

Epstein-Barr virus (EBV) infection and its sequelae in the immunocompetent host.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
2025

Non-DLBCL monomorphic and Hodgkin lymphoma PTLD: clinical insights and treatment strategies.

Blood advances
2025

Scaling for African Inclusion in High-Throughput Whole Cancer Genome Bioinformatic Workflows.

Cancers
2025

B-Cell Lymphomas Secrete Novel Inhibitory Molecules That Disrupt HLA Class II-Mediated CD4+ T-Cell Recognition.

Cells
2026

Gynecologic Tract Lymphomas: A Clinicopathological Analysis of a Single Institution Case Series.

International journal of surgical pathology
2025

Inhibiting the RNA helicase DDX3X in Burkitt lymphoma induces oxydative stress and impedes tumor progression in xenografts.

Frontiers in cell and developmental biology
2025

"In situ" MYC rearrangement and amplification as a secondary change in a case of High-grade B cell lymphoma with 11q aberration.

Annals of hematology
2025

Novel Cereblon-Binding Immunomodulators Have Increased Potency Against Gammaherpesvirus- Associated Lymphomas In Vitro.

Journal of medical virology
2025

Complicated appendicitis as a rare presentation of Burkitt's lymphoma: a case report.

Journal of surgical case reports
2025

Clinicopathological and neuroradiological presentation in an immuno-deficiency patient with central nervous system recurrence of Burkitt lymphoma: an extremely rare case with complete remission achieved twice after GMALL-B-ALL/NHL2002 and R-MIV protocols.

Folia neuropathologica
2025

An immunohistochemical germinal center B-cell dark zone signature identifies Burkitt lymphoma and molecular high-grade B-cell lymphomas.

American journal of clinical pathology
2025

Global, regional, and national epidemiology of childhood Burkitt Lymphoma from 1990 to 2021: statistical analysis of incidence, mortality, and DALYs.

Frontiers in public health
2025

X-linked Lymphoproliferative Disease Type 1 Presenting as Lymphoma in a Male Patient With Atypical Common Variable Immunodeficiency Features: A Case of Delayed Diagnosis.

Cureus
2025

Outcomes of patients with HIV-associated Burkitt lymphoma treated with R-DA-EPOCH regimen: A single-center experience in Shanghai, China.

Chinese medical journal
2025

Efficacy and safety of rituximab-based chemoimmunotherapy in adult patients with Burkitt lymphoma in Korea.

Frontiers in oncology
2025

Application of an obstetric comorbidity index to predict childhood cancer risk: a population based case-control study in Denmark.

British journal of cancer
2025

EBV Latency Programs: Molecular and Epigenetic Regulation and Its Role in Disease Pathogenesis.

Journal of medical virology
2025

Distinct structural and numerical chromosome abnormalities determine the MYC status in diffuse large B-Cell lymphoma and help differentiate from Burkitt lymphoma: a cytogenetic data analysis using unsupervised and AI-driven prediction models.

Annals of hematology
2025

Unexplained Bilateral Adrenal Hemorrhage and Adrenal Insufficiency Unveiling Burkitt's Lymphoma.

AACE endocrinology and diabetes
2025

Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial.

Blood advances
2025

High-grade B-cell lymphoma, not otherwise specified: an LLMPP study.

Blood advances
2025

Ambient Fine Particulate Matter, Residential Greenness, and Childhood Cancer Risk by Trimester of Exposure in Minnesota 2000 to 2014: A Case-Control Study.

Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
2025

Histone variant H2A.Z cooperates with EBNA1 to maintain Epstein-Barr virus latent epigenome.

mBio
2025

A genome-wide association study identifies an African-specific locus on chromosome 21q22.12 associated with Burkitt lymphoma risk and survival.

Leukemia
2025

Palmitoylation by ZDHHC family members regulate B-cell lymphoma growth.

International journal of biological macromolecules
2025

Shining stars in the sky on the gastric mucosa.

Journal of general and family medicine
2025

Mitoxantrone in combination with clofarabine (MITCL) in children, adolescents and young adults with relapsed/refractory acute leukaemia: final results of a phase I/II trial.

EClinicalMedicine
2025

Epstein-Barr virus (EBV) infection of endothelial cells via endocytosis is associated with a poor prognosis in nasopharyngeal carcinoma.

Microbiology spectrum
2025

Epstein-Barr virus type 2 infection is associated with higher viral loads in pediatric tonsils from western Kenya.

Microbiology spectrum
2025

Circulating Tumor DNA in Pediatric Mature B-Cell Non-Hodgkin Lymphoma for Genotyping and Minimal Disease Monitoring.

Pediatric blood &amp; cancer
2025

[The Effect of Histone Deacetylase on the Pathogenesis of Burkitt Lymphoma].

Zhongguo shi yan xue ye xue za zhi
2025

MiR-320a expression shows correlation with viral load in EBV-negative Burkitt lymphoma samples.

Nucleosides, nucleotides &amp; nucleic acids
2025

Ileocolic intussusception as the initial presentation of Burkitt lymphoma in a 27-year-old male: a case report.

Journal of surgical case reports
2025

Increased and persistent absolute CD4+ T cell count in an HIV-associated Burkitt lymphoma patient with central nervous system involvement after axicabtagene ciloleucel therapy.

Cancer biology &amp; medicine
2025

TCF3 and ID3 Regulate TSPAN32 Expression in Burkitt Lymphoma.

Scandinavian journal of immunology
2025

Association of Epstein-Barr virus genomic alterations with human pathologies.

Blood
2024

CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies.

Blood neoplasia
2025

Burkitt Lymphoma in a Child With Down Syndrome: A Rare Clinical Association.

Pediatric blood &amp; cancer
2025

Severe Hypercalcemia in Burkitt Lymphoma Following Heart Transplant in an Elderly Male.

Cureus
2025

Novel PI3Kδ inhibitor exerts antitumor activity in Burkitt lymphoma by inducing ROS-dependent apoptosis.

Medical oncology (Northwood, London, England)
2025

Low-Dose Salinomycin Alters Mitochondrial Function and Reprograms Global Metabolism in Burkitt Lymphoma.

International journal of molecular sciences
2025

Locus-specific human endogenous retroviruses reveal lymphoma subtypes.

iScience
2025

CAR T- cell therapy provides an opportunity for further consolidation treatment for relapsed or refractory adult Burkitt lymphoma patients.

Frontiers in oncology
2025

Prophylactic and Therapeutic EBV Vaccination.

Current topics in microbiology and immunology
2025

Burkitt lymphoma: click here to add to CAR-T?

Blood
2025

When the mouth speaks first: oral Burkitt lymphoma unmasks HIV in a young male.

Oral oncology
2025

Clinicopathological features and prognostic factors of AIDS-related lymphoma: a retrospective single-center study in China.

Annals of hematology
2025

From Biopsy to Diagnosis: Navigating Aggressive B-Cell Lymphomas in Practice.

Medicina (Kaunas, Lithuania)
2025

OCT4 and Nestin Expression in the Microenvironment of Primary Central Nervous System Lymphomas.

International journal of hematology-oncology and stem cell research
2025

PMS2-related constitutional mismatch repair deficiency in a patient with unilateral retinoblastoma and negative germline RB1.

Ophthalmic genetics
2025

SOHO State of the Art Updates and Next Questions | High-Grade B-Cell Lymphomas: Pathologic and Molecular Classification and Therapeutic Implications.

Clinical lymphoma, myeloma &amp; leukemia
2025

Chronic lymphocytic leukemia/small lymphocytic lymphoma and Burkitt lymphoma: A unique case of a composite lymphoma of different clonal origins.

Indian journal of pathology &amp; microbiology
2025

Pathological Findings, Clinical Characteristics, and Outcomes of Thyroid Lymphomas: A Single Tertiary Care Hospital Experience.

Cureus
2025

Evaluation of the Antitumoral Effect of PI3K/AKT/mTOR Pathway Inhibition and Antioxidant Combination on Burkitt Lymphoma Cell Line.

Current cancer drug targets
2025

Epstein-Barr virus latent membrane protein 1 subverts IMPDH pathways to drive B-cell oncometabolism.

PLoS pathogens
2025

Comparative global burden analysis of lymphoma subtypes: a statistical evaluation of severity across global regions.

Frontiers in public health
2025

Pediatric Malignant Tumors in Malawi: A Diagnostic Report From the Kamuzu Central Hospital Pathology Laboratory 2011-2020.

Pediatric blood &amp; cancer
2025

DNA Methylation Epitypes of Burkitt Lymphoma with Distinct Molecular and Clinical Features.

Blood cancer discovery
2025

Phosphatidylinositol 3-Kinase Inhibition and Allogeneic Stem Cell Transplantation Can Overcome Chemotherapy Resistance in Refractory Burkitt Lymphoma.

Journal of hematology
2025

Primary Lymphoma of the Gynecologic Tract: A Comprehensive Pathologic Analysis of 15 Cases.

Diagnostics (Basel, Switzerland)
2025

Optimizing Outcomes in Childhood Mature B-cell Non-Hodgkin Lymphoma: Insights Into Staging, Risk Stratification, and Response Evaluation.

Journal of pediatric hematology/oncology
2025

Spatial and Temporal Distribution of Pediatric Cancers in Southern Ghana: A Retrospective Observational Study.

Health science reports
2025

Dual targeting of EZH2 and PD-L1 in Burkitt's lymphoma enhances immune activation and induces apoptotic pathway.

Frontiers in immunology
2025

Holy water not so holy: Potential source of Elizabethkingia pneumonia and bacteremia in an immunocompromised host.

IDCases
2025

Sporadic Burkitt Lymphoma Presenting as Peritoneal Lymphomatosis-A Case Report.

Diagnostic cytopathology
2025

Primary central nervous system Burkitt lymphoma in a 38-year-old immunocompetent woman: A case report.

Medicine
2025

CD28-costimulated CD19 CAR-T cells for pediatric mature non-Hodgkin B-cell lymphoma.

Bone marrow transplantation
2025

JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma 6. Burkitt lymphoma/high-grade B-cell lymphoma (BL/HGBL).

International journal of hematology
2025

The single-cell immune landscape of HIV-associated aggressive B-cell lymphoma.

Journal of the National Cancer Center
Ver todos os 2.017 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Linfoma de Burkitt.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Linfoma de Burkitt

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Single-cell profiling of HDAC inhibitor-induced EBV lytic heterogeneity defines abortive and refractory states in B lymphoblasts.
    PLoS pathogens· 2026· PMID 41871169mais citado
  2. Association of MMP-2 and MMP-9 Polymorphisms and the Pathogenesis of Childhood Burkitt's Lymphoma.
    Pediatric blood &amp; cancer· 2026· PMID 41834306mais citado
  3. Epstein-Barr virus-associated lymphoma: current understanding and treatment strategies.
    Blood research· 2026· PMID 41793645mais citado
  4. Global Patterns, Temporal Trends, and Potential Non-Infectious Risk Factors for Burkitt Lymphoma from 1990 to 2021.
    Blood and lymphatic cancer : targets and therapy· 2026· PMID 41532019mais citado
  5. Implementation Science Methodology for the Successful Introduction of High-Dose Methotrexate for the Treatment of Pediatric Mature B-Cell Non-Hodgkin Lymphoma in a Resource-Limited Setting.
    Pediatric blood &amp; cancer· 2026· PMID 41491667mais citado
  6. The Growth Supporting Role of ZDHHC11 Is Linked to the MEF2B-BCL6 Regulatory Circuit in Burkitt Lymphoma.
    Int J Cancer· 2026· PMID 41992423recente
  7. [Analysis of the disease burden of Burkitt lymphoma in China from 1990 to 2021].
    Zhonghua Xue Ye Xue Za Zhi· 2026· PMID 41991310recente
  8. Neoplastic Cauda Equina Syndrome: When Do We Not Operate?
    Neurosurg Pract· 2026· PMID 41982315recente
  9. Blood cell-derived transplants at 40.
    Bone Marrow Transplant· 2026· PMID 41981080recente
  10. Exploring EBNA3C Genetic Variability and Recombination in Epstein-Barr Virus-Associated Cancers.
    Int J Mol Sci· 2026· PMID 41977241recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:543(Orphanet)
  2. OMIM OMIM:113970(OMIM)
  3. MONDO:0007243(MONDO)
  4. GARD:5973(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Artigo Wikipedia(Wikipedia)
  8. Q1016605(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Linfoma de Burkitt
Compêndio · Raras BR

Linfoma de Burkitt

ORPHA:543 · MONDO:0007243
Prevalência
Unknown
Herança
Not applicable
CID-10
C91.8 · Leucemia linfóide
CID-11
Ensaios
7 ativos
Início
All ages
Prevalência
12.5 (Africa)
MedGen
UMLS
C0006413
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades